Table 10.

Emerging treatments

Class	Agent	Dose	Mechanism of action	Main indication	Comments
ANGPTL3 inhibitors	Evinacumab	15 mg/kg IV every 4 weeks	Global lipid reduction	LDL-C reduction in HoFH; TG reduction	↓ LDL-C by 30%-50% and ↓ TG by 25%-45%
	Vupanorsen	40-80 mg SC every 4 weeks	Global lipid reduction	LDL-C reduction in HoFH; TG reduction	↓ LDL-C by 30%-50% and ↓ TG by 25%-45%
	AROANG3	50-200 mg SC every 2-4 weeks	Global lipid reduction	LDL-C reduction in HoFH; TG reduction	↓ LDL-C by 30%-50% and ↓ TG by 25%-45%
Apo C-III inhibitors	Volanesorsen	300 mg SC every 1 week	ASO knocks down apo C-III	TG reduction	↓ TG by 50%-70%
	AKCEA-apoC3-LRX	Undetermined	ASO knocks down apo C-III	TG reduction	↓ TG by 50%-70%; GalNAc linked
	AROAPOC3	50 mg SC every 12 weeks	siRNA knocks down apo C-III	TG reduction	↓ TG by 50%-70%
anti-Lp(a)	Olpasiran	Undetermined	siRNA knocks down Lp(a)	Lp(a) reduction	↓ Lp(a) by 50%-70%
	Pelacarsen	80 mg SC every 4 weeks	ASO knocks down Lp(a)	Lp(a) reduction	↓ Lp(a) by 50%-70%
Other	Gemcabene	300-900 mg/d	Unclear	LDL-C reduction	↓ LDL-C by 15%-25% as monotherapy or added to statin

Abbreviations: ANGPTL3, angiopoietin-like protein 3; apo, apolipoprotein; ASO, antisense oligonucleotide; GalNAc, conjugated with N-acetylgalactosamine; HoFH, homozygous familial hypercholesteremia; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); SC, subcutaneous; siRNA, small interfering RNA; TG, triglyceride.